Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31231467 | 0.98 | HSD17B10 (0.34) | HSD17B10HAO1ROCK2CCR1CCR8 | |
| SCHEMBL12680095 | 0.88 | IDH1 (0.43) | HAO1 | |
| SCHEMBL1201341 | 0.82 | NPC1 (0.32) | HSD17B10RAB9A | |
| SCHEMBL30414937 | 0.79 | NOS3 (0.40) | — | |
| SCHEMBL30414750 | 0.78 | ESR1 (0.32) | HAO1 | |
| SCHEMBL14701593 | 0.77 | ALDH1A1 (0.46) | HSD17B10RAB9ANOTUMKDM4E | |
| SCHEMBL30414485 | 0.76 | — | — | |
| SCHEMBL30415010 | 0.76 | CALM1 (0.34) | HAO1RAB9A | |
| SCHEMBL30414242 | 0.75 | ENPP3 (0.35) | CCR1CCR8RAB9AKDM4E | |
| SCHEMBL30414462 | 0.74 | CYP3A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836041-B | Process for producing optically active compound | 住友化学株式会社 | 2024-09-17 | — | — | CN | disclosed |
| US-20230257408-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4186882-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-31 | — | — | EP | disclosed |
| CN-115836041-A | Process for producing optically active compound | 住友化学株式会社 | 2023-03-21 | — | — | CN | disclosed |
| EP-2264005-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-8309753-B2 | Method for producing optically active cyanohydrin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264005-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257408-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SIRT1, SIRT3, HCCS | HSD17B10 472/4885HAO1 2800/4885ROCK2 275/4885 |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | HSD17B10 1417/4885HAO1 938/4885ROCK2 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.